Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2014 / Mar / Statins Protect Elderly Against Macular Degeneration
Retina

Statins Protect Elderly Against Macular Degeneration

If you’re aged over 68 years, then statins significantly reduce your risk of developing AMD; it has no impact on younger age groups.

By Mark Hillen 3/10/2014 1 min read

Share

statins

While the treatment of wet age-related macular degeneration (AMD) has been a success story over the last decade, dry AMD treatment has stalled and little progress has been made in preventing AMD from developing in the first place. Against this background, a team of researchers from the University of California, San Francisco, and Stanford University examined the US National Health and Nutrition Examination Survey (NHANES) dataset to determine whether statin use exhibited a protective effect against AMD (1).

Why statins? Classically, they are used to reduce serum lipoprotein levels, treating dyslipidaemias like atherosclerosis. Statins have shown great benefit in reducing cardiovascular mortality and morbidity, and have prevented (or delayed) millions of heart attacks since their introduction – cardiologists half-joke that they should be offered as a condiment at fast-food restaurants (2).

Many of the risk factors that are associated with cardiovascular disease are also risk factors for AMD, including cigarette smoking, elevated serum cholesterol and hypertension. So the authors set out to determine if lipid-lowering medications exert a preventive effect in AMD development. To find out, they examined 5,604 patients aged over forty years from the NHANES dataset for the presence of AMD, statin use, comorbidities and health-related behaviors like cigarette smoking. The mean age of patients without a history of AMD was 55 years, and with AMD was 68 years. This stratification by age provided an important insight: after adjustment for confounding factors, individuals aged 68 years or more who took statins were significantly less likely to have AMD than those who did not (odds ratio: 0.64, p=0.002). In those aged between 40 and 67 years, no significant association was found between the prevalence of AMD and statin consumption. The authors concluded that “statin intake […] significantly lowers the odds for AMD in individuals 68 years of age or older”.  As dry AMD was the more common form of the disease in the study, perhaps the authors’ findings may open a new therapeutic avenue for the treatment of dry AMD?

References

  1. D.T.Q. Barbosa et al., “Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005–2008”, Eye (2014). Epub ahead of print, doi: 10.1038/eye.2014.8. E.A. Ferenczi et al., “Can a Statin Neutralize the Cardiovascular Risk of Unhealthy Dietary Choices?”, Am. J. Cardiol, 106, 4, 587–592 (2010). doi: 10.1016/j.amjcard.2010.03.077.

About the Author(s)

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

More Articles by Mark Hillen

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: